Relmada Therapeutics (RLMD) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

RLMD Relmada Therapeutics

Watchlist

0.363
+0.010+2.89%

Close Dec 20 16:00 ET

0.372
+0.009+2.56%

Post 20:01 ET

10.95MMarket Cap-0.13P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Relmada Therapeutics Shifts Focus After Study Discontinuation
TipRanksDec 9 08:35 ET
Relmada Therapeutics Exploring Sale After Lead Program Failure
WSJDec 9 07:59 ET
Relmada Therapeutics Announces Discontinuation of Reliance II and Relight Phase 3 Studies, Explores Strategic Alternatives
Quiver QuantitativeDec 9 07:41 ET
Express News | Relmada Therapeutics Inc: To Explore Strategic Alternatives
ReutersDec 9 07:32 ET
Express News | Relmada Therapeutics Inc: Will Continue to Advance Phase 1 Study of Rel-P11, an Investigational Agent for Treatment of Metabolic Disease
ReutersDec 9 07:32 ET
Express News | Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of Rel-1017
ReutersDec 9 07:30 ET

Comments

Trytosaveabit

Dec 9 06:36

T 1 news halt!

$Relmada Therapeutics (RLMD.US)$ Press Release: Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017
Dow Jones· 5 mins ago
Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017
Relmada Therapeutics has Commenced a Process to Explore Strategic Alternatives to Maximize Shareholder Value